Latest Lymphoma Stories
The event is less than 10 days away as the LaFontaine Auto Group announces its annual 9 & WINE Event to help raise funds for the Leukemia & Lymphoma Society. DETROIT, Michigan (PRWEB) May 13, 2013 Local MI dealers are working together as the LaFontaine Auto Group is helping to raise $200,000 for the Leukemia & Lymphoma Society. Every year the Auto Group holds its 9 & WINE Event, which themes the 80s decade with music and dance, as Ryan LaFontaine rallies together as much...
INDIANAPOLIS, May 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new...
Firm’s Senior Manager of Corporate Social Responsibility among 20 D.C.-area candidates aiming to raise $1.2 million for LLS National Capital Chapter in just 10 weeks. McLean, Virginia (PRWEB) May 06, 2013 MorganFranklin Consulting, a leading business consulting and technology solutions company based in McLean, Va., and London, announced today that Jeana Foster, the firm’s Senior Manager of Corporate Social Responsibility (CSR), has been named a candidate in the Leukemia & Lymphoma...
RARITAN, N.J., May 6, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc. Several EAP sites are in the process of opening the clinical trial and information about the program is posted on...
MI car dealers as part of the LaFontaine Automotive Group announces they are looking to help raise money for the Leukemia & Lymphoma Society. The Group is proud to sponsor an evening of 80s fun at its 9 & WINE Benefit. Detroit, Michigan (PRWEB) May 02, 2013 Organizations like the Leukemia & Lymphoma Society count on the help and support of local and far-reaching companies like local MI car dealers and the LaFontaine Automotive Group. With less than three weeks to go, Team...
Faster approvals needed for coverage by provincial drug plans: Lymphoma Foundation Canada TORONTO, April 24, 2013 /CNW/ - The recent approval by Health Canada of a highly effective new treatment for non-Hodgkin lymphoma and the subsequent decision by several provinces to cover the cost for cancer patients is very good news, says Lymphoma Foundation Canada (LFC). However, the organization says more must be done to speed up the coverage by provincial drug plans for a host of...
Voices Against Brain Cancer (VABC), the organization dedicated to brain cancer research and advocacy, responds to an article published on biosciencetechnology.com that examines a Phase 2 clinical trial study focusing on a new brain cancer treatment. New York, NY (PRWEB) April 22, 2013 On April 22, Voices Against Brain Cancer (VABC), an organization dedicated to brain cancer research and advocacy, comments on an article published by Biosciencetechnology.com that discusses a new Phase 2...
SUNNYVALE, Calif., April 18, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), (RESONATE(TM)) was achieved on April 3, 2013. As of today, additional 41 patients were screened and are allowed to participate in this study which has now been...
SEATTLE, April 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, issued draft guidance on PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL). The draft guidance does...
Despite comparable pre-surgery risk scores, patients with radiation heart disease found to be at much greater risk years after surgery Patients who have open heart surgery for heart disease caused by radiation cancer treatment are nearly twice as likely to die in the years following their surgery compared to similar patients who did not undergo radiation treatment, according to new research from Cleveland Clinic published today in the American Heart Association journal Circulation. The...
